Canopy Growth (CGC) Stock Price, Quote, News & History

Q: What sector and industry does Canopy Growth (CGC) operate in?

Canopy Growth is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

Canopy Growth (CGC) Stock Price, Quote, News & History

CGCNASDAQ

Logo brought to you by Benzinga Data

Trade with Public

$1.09

At close: Feb 2, 4:00 PM EST

$1.10

0.010.92%

After Hours: Jan 30, 7:59 PM EST

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Key Statistics

Open

Volume / Avg.

0 / 30.31M

Day Range

- - -

52 Wk Range

0.77 - 2.90

Market Cap

$415.65M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

8.09%

Days to Cover

Recent Canopy Growth Corp News

Canopy Growth Stock Gains As Trump Cannabis Order Reshapes Tax Rules

Canopy Growth shares are up following President Donald Trump's recent executive order urging the Department of Justice to reschedule cannabis to Schedule 3.

Henry Khederian

Trump's Cannabis Rescheduling Order Could Finally Kill A Crushing Tax Rule And Transform US Weed Stocks, Says Expert

Dan Ahrens analyzes Trump's historic cannabis shift. Learn how Schedule 3 could end the 280E "narcotics trafficker" tax for US pot stocks.

Rishabh Mishra

Benzinga Bulls And Bears: Carnival, Caterpillar, Meta — And Markets Make Modest Gains

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Benzinga Senior Editor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-88.43M

Investing Cash Flow (TTM)

229.00K

Financing Cash Flow (TTM)

148.40M

Free Cash Flow (TTM)

-96.14M

Capital Expenditure (TTM)

-7.71M

Net Change in Cash (TTM)

60.20M

Analyst Trends and Forecast

Nov 25

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

1.4

Strong Sell

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$391.33M

PE Ratio (TTM)

PE Ratio (FWD)

PEG Ratio (TTM)

PS Ratio (TTM)

0.97

PB Ratio (TTM)

0.76

Earnings Yield % (TTM)

-180.70%

Earnings Yield % (FWD)

-20.98%

EV / EBITDA (TTM)

Price / EBITDA (TTM)

Price / Free Cash Flow (TTM)

Book Value / Share

$1.44

Company Debt

Total Debt

$228.18M

LT Debt

$226.33M

LT Debt Issuance (TTM)

LT Debt Repayment (TTM)

-$347.21M

Total Cash

$298.06M

Debt to Equity

0.35

Issuance of Debt (TTM)

-$347.21M

Repayment of Debt (TTM)

-$347.21M

Key Statistics

Open

Volume / Avg.

0 / 30.31M

Day Range

- - -

52 Wk Range

0.77 - 2.90

Market Cap

$415.65M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

8.09%

Days to Cover

About

Sector

Health Care

Industry

Pharmaceuticals

Canopy Growth Corp, cultivates and sells medicinal and recreational cannabis and hemp through a portfolio of brands that include Doja, LivRelief, Ace Valley, Deep Space, and others. The Company is engaged in reportable segments namely: Canada cannabi...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Canopy Growth (CGC) stock?

You can purchase shares of Canopy Growth (NASDAQ:CGC) through any online brokerage.

View our list of the best stock brokerages

Who are Canopy Growth (CGC) competitors?

Other companies in Canopy Growth’s space includes: Atea Pharmaceuticals Inc (NASDAQ:AVIR), Zevra Therapeutics Inc (NASDAQ:ZVRA), SNDL Inc (NASDAQ:SNDL), Bioage Labs Inc (NASDAQ:BIOA) and NervGen Pharma Corp (NASDAQ:NGEN).

What is the forecast, or price target, for Canopy Growth (CGC) stock?

Canopy Growth has a consensus price target of $1.59.

What is the current price for Canopy Growth (CGC)?

The stock price for Canopy Growth (NASDAQ: CGC) is $1.1 last updated January 30, 2026 at 7:59 PM EST.

Does Canopy Growth (CGC) pay a dividend?

There are no upcoming dividends for Canopy Growth.

When is Canopy Growth (NASDAQ:CGC) reporting earnings?

Canopy Growth does not have any upcoming earnings scheduled.

Is Canopy Growth (CGC) going to split?

There is no upcoming split for Canopy Growth.

What sector and industry does Canopy Growth (CGC) operate in?

Canopy Growth is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

People Also Watch

Atea Pharmaceuticals Inc

NASDAQ:AVIR

$3.76

-11.32%

Zevra Therapeutics Inc

Neumora Therapeutics Inc

NASDAQ:NMRA

$2.00

0.52%

Aardvark Therapeutics Inc

NASDAQ:AARD

$12.99

Aquestive Therapeutics Inc

NASDAQ:AQST

$2.97

0.52%

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Key Statistics

Open

Volume / Avg.

0 / 30.31M

Day Range

- - -

52 Wk Range

0.77 - 2.90

Market Cap

$415.65M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

8.09%

Days to Cover

Recent Canopy Growth Corp News

Canopy Growth Stock Gains As Trump Cannabis Order Reshapes Tax Rules

Canopy Growth shares are up following President Donald Trump's recent executive order urging the Department of Justice to reschedule cannabis to Schedule 3.

Henry Khederian

Trump's Cannabis Rescheduling Order Could Finally Kill A Crushing Tax Rule And Transform US Weed Stocks, Says Expert

Dan Ahrens analyzes Trump's historic cannabis shift. Learn how Schedule 3 could end the 280E "narcotics trafficker" tax for US pot stocks.

Rishabh Mishra

Benzinga Bulls And Bears: Carnival, Caterpillar, Meta — And Markets Make Modest Gains

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Benzinga Senior Editor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-88.43M

Investing Cash Flow (TTM)

229.00K

Financing Cash Flow (TTM)

148.40M

Free Cash Flow (TTM)

-96.14M

Capital Expenditure (TTM)

-7.71M

Net Change in Cash (TTM)

60.20M

Analyst Trends and Forecast

Nov 25

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

1.4

Strong Sell

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$391.33M

PE Ratio (TTM)

PE Ratio (FWD)

PEG Ratio (TTM)

PS Ratio (TTM)

0.97

PB Ratio (TTM)

0.76

Earnings Yield % (TTM)

-180.70%

Earnings Yield % (FWD)

-20.98%

EV / EBITDA (TTM)

Price / EBITDA (TTM)

Price / Free Cash Flow (TTM)

Book Value / Share

$1.44

Company Debt

Total Debt

$228.18M

LT Debt

$226.33M

LT Debt Issuance (TTM)

LT Debt Repayment (TTM)

-$347.21M

Total Cash

$298.06M

Debt to Equity

0.35

Issuance of Debt (TTM)

-$347.21M

Repayment of Debt (TTM)

-$347.21M

Key Statistics

Open

Volume / Avg.

0 / 30.31M

Day Range

- - -

52 Wk Range

0.77 - 2.90

Market Cap

$415.65M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

8.09%

Days to Cover

About

Sector

Health Care

Industry

Pharmaceuticals

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry